Data / Form D filings / Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc.: Form D filing
Tempest Therapeutics, Inc., a biotechnology company in Brisbane, CA, filed a Form D with the SEC in 2026. The latest, on October 14, 2026, reports $7.5 million sold of a $7.5 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2000 SIERRA POINT PARKWAY, SUITE 400, Brisbane, CA, 94005
- Phone
- (415) 798-8589
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1544227
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 14 | New notice | $7,500,000 | $7,500,000 | 1 | Sep 15 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Matthew Angel | Executive Officer, Director | President and Chief Executive Officer |
| Constance Ames | Executive Officer | Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary |
| John David Yee | Director | |
| William Drake Richey | Director | |
| Nancy Freda-Smith | Director | |
| John Wilbert Frederick | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $22.9 million · Oct 21
- Theravie Pharma, Inc. $750,000 · Oct 19
- Adela, Inc. $12 million · Oct 19
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16
- Renue Life Sciences, Inc. $250,000 · Oct 14
- Lionheart Health, Inc. $387,500 · Oct 7
Every Form D from the week of Oct 12 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Tempest Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.